Cancer-associated mesothelial cells are regulated by the anti-Müllerian hormone axis.

[1]  Linda T. Nieman,et al.  Satellite repeat RNA expression in epithelial ovarian cancer associates with a tumor-immunosuppressive phenotype , 2022, The Journal of clinical investigation.

[2]  S. Kaufmann,et al.  Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer , 2021, Cancer research.

[3]  E. Rankin,et al.  Cancer-associated mesothelial cells promote ovarian cancer chemoresistance through paracrine osteopontin signaling. , 2021, The Journal of clinical investigation.

[4]  K. Izumi,et al.  Roles of CCL2-CCR2 Axis in the Tumor Microenvironment , 2021, International journal of molecular sciences.

[5]  P. Boor,et al.  Interleukin-1α Is a Central Regulator of Leukocyte-Endothelial Adhesion in Myocardial Infarction and in Chronic Kidney Disease , 2021, Circulation.

[6]  P. Colombo,et al.  Anti-Müllerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival , 2021, International journal of oncology.

[7]  P. Donahoe,et al.  Single-cell sequencing reveals suppressive transcriptional programs regulated by MIS/AMH in neonatal ovaries , 2021, Proceedings of the National Academy of Sciences.

[8]  H. Tomita,et al.  Ovarian Cancer-Associated Mesothelial Cells: Transdifferentiation to Minions of Cancer and Orchestrate Developing Peritoneal Dissemination , 2021, Cancers.

[9]  R. Brekken,et al.  Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer , 2021, bioRxiv.

[10]  J. Tavernier,et al.  Interleukin-1 as Innate Mediator of T Cell Immunity , 2021, Frontiers in Immunology.

[11]  P. Colombo,et al.  Anti-Müllerian hormone (AMH) autocrine signaling promotes survival and proliferation of ovarian cancer cells , 2021, Scientific Reports.

[12]  Y. Pylayeva-Gupta,et al.  IL-12 Family Cytokines in Cancer and Immunotherapy , 2021, Cancers.

[13]  R. Weinberg,et al.  Genetically defined syngeneic mouse models of ovarian cancer as tools for the discovery of combination immunotherapy. , 2020, Cancer discovery.

[14]  A. Piotrowska,et al.  Anti-Müllerian Hormone Type II Receptor Expression in Endometrial Cancer Tissue , 2020, Cells.

[15]  A. Regev,et al.  A single-cell landscape of high-grade serous ovarian cancer , 2020, Nature Medicine.

[16]  G. Hoyne,et al.  Mesothelial cells regulate immune responses in health and disease: role for immunotherapy in malignant mesothelioma. , 2020, Current opinion in immunology.

[17]  R. Xiang,et al.  Metastatic ovarian cancer shapes the abdominal immune microenvironment by manipulating IL20-IL20RA signaling pathway , 2020, The Journal of Immunology.

[18]  D. Visscher,et al.  Signals from the Metastatic Niche Regulate Early and Advanced Ovarian Cancer Metastasis through miR-4454 Downregulation , 2020, Molecular Cancer Research.

[19]  Dan Zhang,et al.  Construction of a human cell landscape at single-cell level , 2020, Nature.

[20]  M. Quinn,et al.  Pre-operative sera interleukin-6 in the diagnosis of high-grade serous ovarian cancer , 2020, Scientific Reports.

[21]  C. Ricciardelli,et al.  Ovarian cancer‐associated mesothelial cells induce acquired platinum‐resistance in peritoneal metastasis via the FN1/Akt signaling pathway , 2020, International journal of cancer.

[22]  J. Hartikainen,et al.  Comparative transcriptome analysis of matched primary and distant metastatic ovarian carcinoma , 2019, BMC Cancer.

[23]  J. Merlin,et al.  Mesothelial cell CSF1 sustains peritoneal macrophage proliferation , 2019, European journal of immunology.

[24]  H. Kajiyama,et al.  CCL2 secreted from cancer-associated mesothelial cells promotes peritoneal metastasis of ovarian cancer cells through the P38-MAPK pathway , 2019, Clinical & Experimental Metastasis.

[25]  R. Behringer,et al.  A gene regulatory network for Müllerian duct regression , 2019, Environmental epigenetics.

[26]  Lei Dong,et al.  CX3CL1-CX3CR1 interaction mediates macrophage-mesothelial cross talk and promotes peritoneal fibrosis. , 2019, Kidney international.

[27]  R. Schreiber,et al.  Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity. , 2019, Cold Spring Harbor perspectives in biology.

[28]  N. Matsuura,et al.  Mesothelial cells facilitate cancer stem‑like properties in spheroids of ovarian cancer cells. , 2018, Oncology reports.

[29]  C. Dinarello.  Overview of the IL‐1 family in innate inflammation and acquired immunity , 2018, Immunological reviews.

[30]  G. Massonnet,et al.  The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophages , 2017, Oncotarget.

[31]  Michael G. Johnson,et al.  Spontaneous recombinase activity of Cre–ERT2 in vivo , 2017, Transgenic Research.

[32]  I. Navarro-Teulon,et al.  The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells , 2017, Oncotarget.

[33]  M. Hashizume,et al.  Cancer-associated peritoneal mesothelial cells lead the formation of pancreatic cancer peritoneal dissemination. , 2017, International journal of oncology.

[34]  S. Mutsaers,et al.  Mesothelial cells and peritoneal homeostasis. , 2016, Fertility and sterility.

[35]  Yan Zhou,et al.  Anti-Müllerian Hormone Signaling Regulates Epithelial Plasticity and Chemoresistance in Lung Cancer. , 2016, Cell reports.

[36]  A. Bhatt,et al.  Role of interleukin-6 in cancer progression and therapeutic resistance , 2016, Tumor Biology.

[37]  Cesar M. Castro,et al.  CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis , 2016, PloS one.

[38]  A. Dalgleish,et al.  Human Peritoneal Mesothelial Cells Display Phagocytic and Antigen-Presenting Functions to Contribute to Intraperitoneal Immunity , 2016, International Journal of Gynecologic Cancer.

[39]  P. Donahoe,et al.  Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer. , 2016, Current molecular medicine.

[40]  J. Jimenez-Heffernan,et al.  The Mesothelial Origin of Carcinoma Associated-Fibroblasts in Peritoneal Metastasis , 2015, Cancers.

[41]  Cesar M. Castro,et al.  AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer , 2015, Proceedings of the National Academy of Sciences.

[42]  C. Lim,et al.  Mesothelial cells in tissue repair and fibrosis , 2015, Front. Pharmacol..

[43]  Evan Z. Macosko,et al.  Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets , 2015, Cell.

[44]  J. Duffield,et al.  Lineage tracing reveals distinctive fates for mesothelial cells and submesothelial fibroblasts during peritoneal injury. , 2014, Journal of the American Society of Nephrology.

[45]  B. Herrmann,et al.  Upk3b Is Dispensable for Development and Integrity of Urothelium and Mesothelium , 2014, PloS one.

[46]  Hong-mei Xu.  Th1 cytokine-based immunotherapy for cancer. , 2014, Hepatobiliary & pancreatic diseases international : HBPD INT.

[47]  J. George,et al.  Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. , 2014, The Journal of clinical investigation.

[48]  C. Bascoul-Mollevi,et al.  The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer , 2014, mAbs.

[49]  Rachel D. Mullen,et al.  Molecular Genetics of Müllerian Duct Formation, Regression and Differentiation , 2014, Sexual Development.

[50]  S. Rosenberg.  IL-2: The First Effective Immunotherapy for Human Cancer , 2014, The Journal of Immunology.

[51]  K. Stenvers,et al.  Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time , 2014, Journal of visualized experiments : JoVE.

[52]  D. Bachvarov,et al.  Role of malignant ascites on human mesothelial cells and their gene expression profiles , 2014, BMC Cancer.

[53]  M. López-Cabrera.  Mesenchymal Conversion of Mesothelial Cells Is a Key Event in the Pathophysiology of the Peritoneum during Peritoneal Dialysis , 2014, Advances in medicine.

[54]  P. Donahoe,et al.  Abstract A42: An albumin leader sequence coupled with a cleavage site modification enhances the yield of recombinant c-terminal Mullerian inhibiting substance , 2013 .

[55]  A. Clarkson,et al.  The type 2 anti‐Müllerian hormone receptor has splice variants that are dominant‐negative inhibitors , 2013, FEBS letters.

[56]  N. Hogg,et al.  PHAGOCYTES , GRANULOCYTES , AND MYELOPOIESIS Mast cell and macrophage chemokines CXCL 1 / CXCL 2 control the early stage of neutrophil recruitment during tissue in fl ammation , 2013 .

[57]  Y. Hayashizaki,et al.  LRRN4 and UPK3B Are Markers of Primary Mesothelial Cells , 2011, PloS one.

[58]  M. Anttonen,et al.  Anti-Müllerian hormone inhibits growth of AMH type II receptor-positive human ovarian granulosa cell tumor cells by activating apoptosis , 2011, Laboratory Investigation.

[59]  H. Cremer,et al.  Use of ERT2‐iCre‐ERT2 for conditional transgenesis , 2008, Genesis.

[60]  W. Cruikshank,et al.  Preferential Migration of T Regulatory Cells Induced by IL-161 , 2007, The Journal of Immunology.

[61]  S. Szabo,et al.  Molecular mechanisms regulating Th1 immune responses. , 2003, Annual review of immunology.

[62]  R. Behringer,et al.  Requirement of Bmpr1a for Müllerian duct regression during male sexual development , 2002, Nature Genetics.

[63]  S. Mutsaers.  Mesothelial cells: Their structure, function and role in serosal repair , 2002, Respirology.

[64]  P. Donahoe,et al.  Mullerian-inhibiting substance regulates NF–κB signaling in the prostate in vitro and in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[65]  F.J. Sauvage,et al.  Development of Th1-type immune responses requires the type I cytokine receptor TCCR , 2000, Nature.

[66]  M. Jordana,et al.  IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. , 1998, The Journal of clinical investigation.

[67]  N. Kohno,et al.  Interleukin 6 is an autocrine growth factor for normal human pleural mesothelial cells. , 1996, American journal of respiratory cell and molecular biology.

[68]  H. Verbrugh,et al.  Neutrophil adherence to and migration across monolayers of human peritoneal mesothelial cells. The role of mesothelium in the influx of neutrophils during peritonitis. , 1996, The Journal of laboratory and clinical medicine.

[69]  H. Zwierzina,et al.  IL-6 secretion by human peritoneal mesothelial and ovarian cancer cells. , 1995, Cytokine.

[70]  C. Harris,et al.  Asbestos-associated chromosomal changes in human mesothelial cells. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[71]  P. Donahoe,et al.  Müllerian duct regression in the embryo correlated with cytotoxic activity against human ovarian cancer. , 1979, Science.

[72]  N. Reyes,et al.  CXCL3 Signaling in the Tumor Microenvironment. , 2021, Advances in experimental medicine and biology.

[73]  E. Terpos,et al.  CCL3 Signaling in the Tumor Microenvironment. , 2020, Advances in experimental medicine and biology.

[74]  F. Guo,et al.  Interleukin-10 Family Cytokines Immunobiology and Structure. , 2019, Advances in experimental medicine and biology.

[75]  K. Ghoreschi,et al.  The Interleukin-1 Family. , 2016, Advances in experimental medicine and biology.

[76]  Yuan Zhang,et al.  Th1/Th2 cell's function in immune system. , 2014, Advances in experimental medicine and biology.

[77]  W. Luttmann,et al.  Human peritoneal mesothelial cells synthesize interleukin-6: Induction by IL-1β and TNFα , 1993 .